BridgeMD
New treatment option for Acute Myocardial Infarction (AMI)
Official title Fast Discharge After Acute Myocardial Infarction Discharge MI
ClinicalTrials.gov ID: NCT06744322
What this study is testing
- What it's testing
- To evaluate the hypothesis that a fast discharge strategy (discharge at 24 [± 12] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
- Age ≥ 18 years at time of consent
- Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-treatment TIMI 3 flow
- Ability to understand and willingness to sign and date written informed consent
You likely can't join if
- Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
- PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade...
- Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or...
- Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
- Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema)
- Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
See the full eligibility criteria
- Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
- Age ≥ 18 years at time of consent
- Invasive management strategy and in case of PCI successful intervention of the culprit lesion defined by post-treatment TIMI 3 flow
- Ability to understand and willingness to sign and date written informed consent
- Myocardial infarction complicated by cardiac arrest (out-of-hospital cardiac arrest/in-hospital cardiac arrest)
- PCI-related complications (coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade ≥2, stroke/thromboembolism, access site complications including...
- Malignant arrhythmias including sustained ventricular arrhythmias and persistent bradycardia (\< 50 beats per minute due to sinus node or atrioventricular conduction system abnormalities, second- /third-degree...
- Ongoing hemodynamic instability (systolic blood pressure \<90 mmHg, elevated lactate concentrations, need for inotropes or vasopressors)
- Ongoing respiratory instability defined by Killip class \>I (rales, pulmonary edema)
- Ongoing quantitative disorders of consciousness (somnolence, sopor, coma)
- Acute kidney injury defined by Kidney Disease Improving Global Outcomes (KDIGO) stages 2 and 3
- Pregnancy
- Untreated critical non-culprit lesions requiring revascularization during index hospitalization not allowing fast discharge
- Immobility/limited mobility or social circumstances that prevent fast discharge assessed by an interprofessional care team
The study team makes the final eligibility decision.
Where it's taking place
- Wiener Neustadt, Lower Austria, Austria
- Schwarzach im Pongau, Schwarzach Im Pongau, Austria
- Salzburg, State of Salzburg, Austria
- Graz, Styria, Austria
- Innsbruck, Tyrol, Austria
- Wels, Upper Austria, Austria
- Feldkirch, Vorarlberg, Austria
- Munich, Bavaria, Germany
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Wiener Neustadt, Lower Austria, Austria; Schwarzach im Pongau, Schwarzach Im Pongau, Austria; Salzburg, State of Salzburg, Austria; Graz, Styria, Austria; Innsbruck, Tyrol, Austria; Wels, Upper Austria, Austria and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.